naa a22 4500 510785743 CHVBK 20180411083301.0 cr unu---uuuuu 180411e20130101xx s 000 0 eng 10.1007/s12603-013-0001-3 doi (NATIONALLICENCE)springer-10.1007/s12603-013-0001-3 Passive immunotherapy for Alzheimer's disease: What have we learned, and where are we headed? [Elektronische Daten] [P. Aisen, B. Vellas] Serdi and Springer-Verlag France, 2013 Aisen P. Alzheimer's Disease Collaborative Study, University of California in San-Diego, San Diego, USA aut Vellas B. Gerontopole, Univeristy of Toulouse, UMR INSERM 1027, University Toulouse 3, CHU Toulouse, Toulouse, France aut The journal of nutrition, health & aging Springer-Verlag 17/1(2013-01-01), 49-50 1279-7707 17:1<49 2013 17 12603 https://doi.org/10.1007/s12603-013-0001-3 text/html Onlinezugriff via DOI 1 editorial jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12603-013-0001-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Aisen P. Alzheimer's Disease Collaborative Study, University of California in San-Diego, San Diego, USA aut NATIONALLICENCE 700 1- Vellas B. Gerontopole, Univeristy of Toulouse, UMR INSERM 1027, University Toulouse 3, CHU Toulouse, Toulouse, France aut NATIONALLICENCE 773 0- The journal of nutrition, health & aging Springer-Verlag 17/1(2013-01-01), 49-50 1279-7707 17:1<49 2013 17 12603 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer